Mājas>Klīniskā pētniecība>Klīniskie izmēģinājumi>LYNX

How to use the speech recognition tool?

NCT01265719

LYNX

Long-Term Non-Interventional Latanoprost Study

Type: Observational



Status of the trial: Completed

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2010-12-23
  • Closing Date: 2017-10-12

Criteria

Inclusion: Diagnosis of pediatric glaucoma or elevated intraocular pressure, continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination

Exclusion: Pregnant or nursing females at baseline, a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost

More information

Children: Yes

Adults: No

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Neuro-Ophthalmology Rare Diseases (WG2)

Subscribe to our mailing list

* indicates required

This ERN is supported by: